Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan

NCT04293887 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT04293887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04293887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan
Lead sponsor
Tongji Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2020
Completion date
June 30, 2020
Enrollment
328 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, recombinant human interferon α1β